FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.
Loriot
Y
Y
Service Innovations Thérapeutiques Précoces (Department of Early Clinical Trials), University Paris XI; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Massard
C
C
Service Innovations Thérapeutiques Précoces (Department of Early Clinical Trials), University Paris XI; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Angevin
E
E
Service Innovations Thérapeutiques Précoces (Department of Early Clinical Trials), University Paris XI; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Lambotte
O
O
Department of Internal Medicine, Assistance publique - Hôpitaux de Paris, Teaching Hospital Bicêtre, Le Kremlin Bicêtre, France.
Escudier
B
B
Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Soria
J-C
JC
Service Innovations Thérapeutiques Précoces (Department of Early Clinical Trials), University Paris XI; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. Electronic address: soria@igr.fr.
D001562:Benzimidazoles / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000150:complications* / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy; D015363:Quinolones / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
C500007:4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one; D001562:Benzimidazoles; D015363:Quinolones; C512478:EGFR protein, human; D066246:ErbB Receptors